StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences r&D by cost type — Personnel, infrastructure and other support costs ($M) ($M)

Form 10-Q / 10-K MD&A Research and Development Expenses

QuarterlyAnnual
Latest, FY2025
3,427
Period ended Dec 31, 2025
Change on a year earlier
-3.6%
3,555 in FY2024
History
9 years
Since FY2016
Sources
6
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedR&D by cost type — Personnel, infrastructure and other support costs ($M) ($M)Year on yearSource
FY2025Dec 31, 20253,427-3.6%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
FY2024Dec 31, 20243,555+11.0%Form 10-K (gild-20251231.htm, filed 2026-02-24) ↗
FY2023Dec 31, 20233,204+14.0%Form 10-K (gild-20241231.htm, filed 2025-02-28) ↗
FY2022Dec 31, 20222,811–Form 10-K (gild-20231231.htm, filed 2024-02-23) ↗
FY2020Dec 31, 20202,260+12.1%Form 10-K (gild-20201231.htm, filed 2021-02-25) ↗
FY2019Dec 31, 20192,016+7.5%Form 10-K (gild-20201231.htm, filed 2021-02-25) ↗
FY2018Dec 31, 20181,876+34.1%Form 10-K (gild-20201231.htm, filed 2021-02-25) ↗
FY2017Dec 31, 20171,399+10.1%Form 10-K (a2019form10-k.htm, filed 2020-02-25) ↗
FY2016Dec 31, 20161,271–Form 10-K (a2018form10-k.htm, filed 2019-02-26) ↗

Cite this data

StockData. (2026). Gilead Sciences R&D by cost type — Personnel, infrastructure and other support costs ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rd_personnel_infra

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.